Review of pneumococcal conjugate vaccine in adults: implications on clinical development (Q35737849)

10 August 2017

1 reference

title

Review of pneumococcal conjugate vaccine in adults: implications on clinical development (English)

1 reference

pneumococcal conjugate vaccine

10 August 2017

1 reference

based on heuristic

inferred from title

author name string

Betsy Abraham-Van Parijs

series ordinal

1

1 reference

PubMed ID

15063558

10 August 2017

language of work or name

English

0 references

publication date

1 March 2004

1 reference

10 August 2017

1 reference

10 August 2017

22

1 reference

10 August 2017

11-12

1 reference

10 August 2017

1362-1371

1 reference

Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance Study in Ohio. The Community-Based Pneumonia Incidence Study Group

10 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.029

Hospitalized community-acquired pneumonia in the elderly: age- and sex-related patterns of care and outcome in the United States.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.029

Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.029

The protective efficacy of polyvalent pneumococcal polysaccharide vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.029

Effectiveness of pneumococcal polysaccharide vaccine in older adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.029

Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration Cooperative Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.029

Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.029

Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.029

Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.029

Reactogenicity and immunogenicity of a protein-conjugated pneumococcal oligosaccharide vaccine in older adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.029

Tolerability and immunogenicity of an 11-valent pneumococcal conjugate vaccine in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.029

Combined schedule of 7-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal vaccine in children and young adults with sickle cell disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.029

Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.029

Effect of human immunodeficiency virus type 1 infection on the antibody response to a glycoprotein conjugate pneumococcal vaccine: results from a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.029

Enhanced antibody response to pneumococcal polysaccharide vaccine after prior immunization with conjugate pneumococcal vaccine in HIV-infected adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.029

Antibody responses to polysaccharide and polysaccharide-conjugate vaccines after treatment of Hodgkin disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.029

Pneumococcal conjugate vaccine primes for antibody responses to polysaccharide pneumococcal vaccine after treatment of Hodgkin's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.029

IgG response to pneumococcal polysaccharide-protein conjugate appears similar to IgG response to polysaccharide in bone marrow transplant recipients and healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.029

IgG responses to protein-conjugated pneumococcal capsular polysaccharides in persons who are genetically incapable of responding to unconjugated polysaccharides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.029

Magnitude, duration, quality, and function of pneumococcal vaccine responses in elderly adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.029

Humoral response to recombinant hepatitis B virus vaccine at birth: role of HLA and beyond.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.029

Low baseline antibody level to diphtheria is associated with poor response to conjugated pneumococcal vaccine in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.029

Booster response to the tetanus and diphtheria toxoid carriers of 11-valent pneumococcal conjugate vaccine in adults and toddlers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.029

Community-acquired pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.029

Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.029

Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.029

BTS Guidelines for the Management of Community Acquired Pneumonia in Adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.029

Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.029

Measuring the comparative efficacy of antibacterial agents for acute otitis media: The “Pollyanna phenomenon”

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.029

The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.029

Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.029

Rethinking recommendations for use of pneumococcal vaccines in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.029

Age-associated differences in immunoglobulin G1 (IgG1) and IgG2 subclass antibodies to pneumococcal polysaccharides following vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.029

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2004.01.029

1 reference

10 August 2017

1 reference

PubMed ID

15063558